Cyteir Therapeutics, Inc.
NASDAQ:CYT
3.02 (USD) • At close March 15, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Assets: | ||||
| Current Assets: | ||||
| Cash & Cash Equivalents
| 147.12 | 189.723 | 10.938 | 29.012 |
| Short Term Investments
| 0 | 0 | 0 | 0 |
| Cash and Short Term Investments
| 147.12 | 189.723 | 10.938 | 29.012 |
| Net Receivables
| 0 | 0.038 | 0.063 | 0.164 |
| Inventory
| 0 | -0.038 | -0.063 | 1.26 |
| Other Current Assets
| 2.089 | 3.354 | 1.193 | 0.001 |
| Total Current Assets
| 149.209 | 193.077 | 12.131 | 30.437 |
| Non-Current Assets: | ||||
| Property, Plant & Equipment, Net
| 1.699 | 2.055 | 1.287 | 0.788 |
| Goodwill
| 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 |
| Long Term Investments
| 0 | 0.256 | 0.256 | 0.144 |
| Tax Assets
| 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 2.324 | 0 | 0.061 | 0 |
| Total Non-Current Assets
| 4.023 | 2.311 | 1.604 | 0.932 |
| Total Assets
| 153.232 | 195.388 | 13.735 | 31.369 |
| Liabilities & Equity: | ||||
| Current Liabilities: | ||||
| Account Payables
| 1.128 | 1.785 | 1.689 | 0.602 |
| Short Term Debt
| 0.889 | 0 | 0 | 0 |
| Tax Payables
| 0 | 0 | 0 | 0 |
| Deferred Revenue
| 0 | 0 | 0 | 0 |
| Other Current Liabilities
| 3.298 | 5.726 | 1.448 | 1.37 |
| Total Current Liabilities
| 5.315 | 7.511 | 3.137 | 1.972 |
| Non-Current Liabilities: | ||||
| Long Term Debt
| 0 | 0 | 0 | 0 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 1.631 | 0.585 | 58.629 | 57.733 |
| Total Non-Current Liabilities
| 1.631 | 0.585 | 58.629 | 57.733 |
| Total Liabilities
| 6.946 | 8.096 | 61.766 | 59.705 |
| Equity: | ||||
| Preferred Stock
| 0 | 195.388 | 57.411 | 57.411 |
| Common Stock
| 0.035 | 0.035 | 0.002 | 0.001 |
| Retained Earnings
| -138.114 | -92.053 | -49.927 | -29.104 |
| Accumulated Other Comprehensive Income/Loss
| 0 | -195.388 | -57.411 | -57.411 |
| Other Total Stockholders Equity
| 284.365 | 279.31 | 1.894 | 0.767 |
| Total Shareholders Equity
| 146.286 | 187.292 | -48.031 | -28.336 |
| Total Equity
| 146.286 | 187.292 | -48.031 | -28.336 |
| Total Liabilities & Shareholders Equity
| 153.232 | 195.388 | 13.735 | 31.369 |